Thus, the PI3Kβ inhibitor, which is thought to regulate AKT activity in tumors with PTEN loss, has been applied to PTEN-deficient melanoma mouse models and demonstrated to enhance the efficacy of both PD-1 and CTLA-4 inhibitors (150). This evidence concerns the gene PDCD1 and melanoma.